The introduction of prostate-specific antigen (PSA) in selecting men for prostate biopsy leads to earlier detection of prostate cancer (PCa) and, perhaps, a reduction in PCa-specific mortality [2]. This evidence concerns the gene KLK3 and prostate carcinoma.